Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes

Oncology

Volumn 62, Issue 4, 2002, Pages 354-362

  Shi, Xin ^a   Liu, Shengli ^a   Kleeff, Jörg ^a,b   Friess, Helmut ^a,b   Büchler, Markus W ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 Fluorouracil; Apoptosis; Bcl 2; Chemotherapy; Gemcitabine; Pancreatic cancer

Indexed keywords

FLUOROURACIL; GEMCITABINE; MESSENGER RNA; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; PANCREAS CANCER; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RHODAMINES; RIBONUCLEASE, PANCREATIC; TUMOR CELLS, CULTURED;

EID: 0036057585     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065068     Document Type: Article

References (47)

1. Cancer statistics, 1997
2. Cancer of the pancreas. 50 Years of surgery
3. Treatment of advanced and metastatic pancreatic cancer
4. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
5. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
6. Chemotherapy in advanced pancreatic adenocarcinoma
7. Chemotherapy for pancreatic carcinoma
8. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine)
9. Gemcitabine: Current status of phase I and II trials
10. Preclinical combination therapy with gemcitabine and mechanisms of resistance
11. Gemcitabine: Preclinical pharmacology and mechanisms of action
12. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
13. Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C and oral dipyridamole in advanced measurable pancreatic cancer: A North Central Cancer Treatment Group trial
14. Changes in cellular glutathione content during Adriamycin treatment in human ovarian cancer - A possible indicator of chemosensitivity
15. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
16. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
17. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
18. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: Characterization of biochemical determinants of antineoplastic drug sensitivity
19. Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma
20. Enhanced expression of the type II transformation growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression
21. Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: Biochemical mechanism of resistance
22. Time-schedule dependency of the inhibiting activity of various anti-cancer drugs in the clonogenic assay
23. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma
24. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
25. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
26. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia
27. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780
28. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves
29. Mismatch repair proficiency and in vitro response to 5-Fluorouracil
30. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line
31. Activation of MAP kinases by 5-fluorouracil in a 5-fluorouracil-resistant variant human cell line derived from a KT breast cancer cell line
32. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells
33. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content
34. The Bcl-2 protein family: Arbiters of cell survival
35. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis
36. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia
37. The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function
38. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer
39. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
40. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage
41. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
42. BCL-2 family protein expression in human malignant glioma: A clinical-pathological correlative study
43. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis
44. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer
45. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
46. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia
47. Identification of a p53-dependent negative response element in the bcl-2 gene